Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who received chemotherapy, a striking result in...
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
Allogene Therapeutics said Monday that its off-the-shelf CAR-T treatment eliminated residual cancer cells in patients with B-cell lymphoma three times better than standard care — achieving...
Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the US....
A smarter approach to dermatology trials—built for durability and real-world impact. Read More
Every day, more than 40 million people ask ChatGPT about health care, according to OpenAI. They’re asking questions about diet, exercise, insurance — and in some...
The spring IPO cohort is starting to take shape. On Friday night, neuroscience drug developer Seaport Therapeutics and blood clotting disorder biotech Hemab Therapeutics both filed...
Solar-driven biosynthesis of chemicals from phosphite-rich wastewater and carbon dioxide
Post Content
Post Content